Reiki Nishimura

Dr. Reiki Nishimura


Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2008 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
RNReiki Nishimura
Reiki Nishimura
NANobuyuki Arima
Nobuyuki Arima

15 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RTRumiko Tashima
Rumiko Tashima
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YNYasuyuki Nishiyama
Yasuyuki Nishiyama
YOYasuhiro Okumura
Yasuhiro Okumura
NANobuyuki Arima
Nobuyuki Arima
The Ki-67 index is an important biomarker for indicating the proliferation of cancer cells and is considered to be an effective prognostic factor for breast cancer. However, a standard cut-off point for the Ki-67 index has not yet been established. Therefore, the aim of this retrospective study was to determine an optimal cut-off point in order to establish it as a more accurate prognostic factor. Immunohistochemical analysis of the Ki-67 index was performed on 4329 patients with primary breast cancer from August 1987 to March 2012. Out of this sample, there were 3186 consecutive cases from September 1997 with simultaneous evaluations of ER, PgR and HER2 status. Cox's proportional hazard model was used to perform univariate and multivariate analyses of the factors related to OS. The hazard ratios (HR) and the p values were then compared to determine the optimal cut-off point for the Ki-67 index. The median Ki-67 index value was 20.5% (mean value 26.2%). The univariate analysis revealed that there was a statistically significant negative correlation with DFS and OS and the multivariate analysis revealed that the Ki-67 index value was a significant factor for DFS and OS. The top seven cut-off points were then carefully chosen based on the results of the univariate analysis using the lowest p-values and the highest HR as the main selection criteria. The multivariate analysis of the factors for OS showed that the cut-off point of 20% had the highest HR in all of the cases. However, the cutoff point of 20% was only a significant factor for OS in the Luminal/HER2- subtype. There was no correlation between the Ki-67 index value and OS in any of the other subtypes. These data indicate that the optimal cut-off point of 20% is the most effective prognostic factor for Luminal/HER2- breast cancer.

22 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YOYasuhiro Okumura
Yasuhiro Okumura
MNMasahiro Nakano
Masahiro Nakano
HOHiroko Otsuka
Hiroko Otsuka
NANobuyuki Arima
Nobuyuki Arima
Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification and is the most aggressive subtype, with a heterogeneous genetic profile. The aim of this retrospective study was to evaluate the clinical significance of menopausal status in breast cancer cases with TNBC. Methods: Primary breast cancer patients who underwent curative surgery were enrolled in this retrospective study. A total of 5153 invasive breast cancer cases with Stage I–III were analyzed. The distribution of cases according to the menopausal status and subtypes was investigated and the clinicopathological characteristics and prognosis were compared between pre- and postmenopausal TNBC patients. Results: TNBC was frequently seen in postmenopausal patients and Luminal B and Luminal/HER2 subtypes were more common in premenopausal patients. There was no difference in DFS in the Luminal A/B and HER2 subtypes, but a significant difference was seen in the TNBC patients. Premenopausal patients with TNBC frequently had an overexpression of the p53 protein, a significantly higher Ki-67 index value, and a higher nuclear grade. A multivariate analysis revealed that menopausal status, nodal status, and tumor size were significant factors for DFS in TNBC cases. Conclusion: Menopausal status significantly correlates with breast cancer subtypes. TNBC was often seen in postmenopausal patients and these patients tend to have more favorable factors and a better DFS than premenopausal patients. These findings suggest that menopausal status is an important factor for evaluating biology and prognosis in TNBC cases.

11 December 2007 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
RNReiki Nishimura
Reiki Nishimura
YOYasuhiro Okumura
Yasuhiro Okumura
NANobuyuki Arima
Nobuyuki Arima

1 July 2003 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
RNReiki Nishimura
Reiki Nishimura
KNKazuharu Nagao
Kazuharu Nagao
HMHaruhiko Miyayama
Haruhiko Miyayama
MMMasakazu Matsuda
Masakazu Matsuda
KBKen-Ichirou Baba
Ken-Ichirou Baba
HYHiroya Yamashita
Hiroya Yamashita

7 June 2022 in Oncology Letters
Verified
Journal Article
Open access
PDF file
RNReiki Nishimura
Reiki Nishimura
TOTomofumi Osako
Tomofumi Osako
YOYasuhiro Okumura
Yasuhiro Okumura
MNMasahiro Nakano
Masahiro Nakano
HOHiroko Ohtsuka
Hiroko Ohtsuka
NANobuyuki Arima
Nobuyuki Arima
Lymphovascular invasion (LVI) is associated with a poor outcome in breast cancer. The purpose of the present study was to evaluate the clinical significance of LVI in primary breast cancer and to investigate disease‑free survival as a prognostic marker according to the breast cancer subtypes. This study examined 4,652 consecutive cases of invasive breast cancer excluding the patients with non‑invasive cancer, stage IV and those who underwent neo‑adjuvant therapy from February 2002 to February 2021. The clinicopathological characteristics and prognosis of LVI‑positive and ‑negative tumors were compared. LVI was evaluated in H&E staining specimens from surgically resected samples. The LVI expression rates were 29.2% (low, 19.7%; high, 9.5%) in all primary cases. The LVI‑positive rate was significantly associated with specimens with the following characteristics: ER/PgR‑negative, HER2‑positive, p53 overexpression, higher Ki‑67 index values, higher nuclear grade, positive nodes and larger tumors. Moreover, the subtypes were significantly associated with LVI positivity; 20% in Luminal A, 34.6% in Luminal B, 40.9% in Lumina/HER2, 38.1% in HER2‑enriched and 29.8% in triple negative (TN). There were significant differences in disease‑free survival between LVI status in Luminal A, Luminal B and TN subtypes, but there was no difference in the Luminal/HER2 and HER2‑enriched subtypes. A multivariate analysis revealed that LVI was a significant factor in Luminal B and TN subtypes. Overall, LVI was significantly associated with the advanced and aggressive characteristics in breast cancer. Luminal A type had a lower LVI rate, and HER2 type had a higher LVI rate. Moreover, LVI was a significant prognostic factor in Luminal B and TN subtypes. These data suggested that the LVI status was useful in predicting the prognosis in HER2 negative breast cancer cases.